Guided Therapeutics Net debt/EBITDA
Quel est le Net debt/EBITDA de Guided Therapeutics?
Le Net debt/EBITDA de Guided Therapeutics, Inc. est -0.52
Quelle est la définition de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA des entreprises dans Health Care secteur sur OTC par rapport à Guided Therapeutics
Que fait Guided Therapeutics?
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Entreprises avec net debt/ebitda similaire à Guided Therapeutics
- Visteon a Net debt/EBITDA de -0.52
- Bouvet ASA a Net debt/EBITDA de -0.52
- TOT BIOPHARM International a Net debt/EBITDA de -0.52
- Coolpad a Net debt/EBITDA de -0.52
- Franchise International a Net debt/EBITDA de -0.52
- Vanadiumcorp Resource a Net debt/EBITDA de -0.52
- Guided Therapeutics a Net debt/EBITDA de -0.52
- Mandalay Resources a Net debt/EBITDA de -0.52
- Midnight Sun Mining a Net debt/EBITDA de -0.51
- Sonoro Gold a Net debt/EBITDA de -0.51
- McEwen Mining a Net debt/EBITDA de -0.51
- SKY Network Television a Net debt/EBITDA de -0.51
- Old Dominion Freight Line a Net debt/EBITDA de -0.51